North America Biobanking Market - 2025-2033

The North America biobanking market reached US$ 1.09 billion in 2024 and is expected to reach US$ 2.27 billion by 2033, growing at a CAGR of 8.6% during the forecast period 2025-2033.

Biobanking refers to the systematic process of collecting, storing, managing and distributing biological samples (such as blood, tissue, DNA, RNA, cells, and bodily fluids) for use in scientific research and clinical applications. These biological specimens are collected from humans, animals, plants, or microorganisms and are stored for future use to understand diseases, develop therapeutic treatments and facilitate personalized medicine.

Biobanks serve as a critical resource for various types of medical and scientific research, including genomic studies, drug discovery, disease tracking and epidemiology. They provide researchers with a reliable and standardized supply of biological material, ensuring the consistency and reproducibility of their studies. They are integral to advancing medical research and improving patient care, especially in the era of personalized medicine.

The biobanking market in North America has been experiencing significant growth due to the increasing demand for biological samples for various scientific and clinical applications. The market demand is driven by factors like advancements in genomics, precision medicine and disease research, as well as the expansion of pharmaceutical and biotechnology industries.

For instance, according to a study conducted by the National Institute of Health, digital biobanks can catalyze scientific research and technological development by facilitating the sharing of curated and standardized imaging data, clinical, pathological and molecular data, which is critical for the development of a comprehensive and personalized data-driven diagnostic approach in disease management, as well as fostering the development of computational prediction models.

Market Dynamics: Drivers & Restraints

Rapid Advancements in Biotechnology & Genomic Research

The rapid advancements in biotechnology & genomic research are significantly driving the growth of the North America biobanking market and are expected to drive the market over the forecast period. Biotechnology and genomics have led to a significant rise in the development of personalized treatments and targeted therapies.

Biobanks play a crucial role by providing the genetic samples necessary to identify biomarkers and genetic variations in diseases like cancer, cardiovascular diseases and neurological disorders. These insights are essential for developing drugs tailored to individual genetic profiles, thus accelerating the demand for biological samples. For instance, companies like Illumina's advancements in genomic sequencing, like next-generation sequencing (NGS), require robust sample storage and data management due to the massive amounts of data generated, enabling applications in genomics, transcriptomics and epigenomics.

In North America, the genomic research sector is booming, with a particular focus on understanding the genetic basis of diseases and advancing tools like CRISPR, next-generation sequencing (NGS) and genetic editing. These technologies require high-quality, well-preserved biological samples for genomic analysis, which increases the demand for well-maintained biobanks.

For instance, the All of Us Research Program in the U.S., initiated by the National Institutes of Health (NIH), aims to collect genomic and health data from over 1 million individuals. This initiative requires an extensive biobank for storing and processing genetic samples to provide insights into diverse genetic markers.

Ethical & Legal Challenges in Sample Collection and Usage

Ethical and legal challenges related to sample collection and usage are significant barriers to the growth of the North America biobanking market. These challenges stem from the complexities involved in ensuring informed consent, privacy protection and data security, as well as navigating the regulatory landscape governing biological samples. These obstacles can delay biobank operations, increase compliance costs and complicate the sample-sharing process.

One of the primary ethical challenges in biobanking is obtaining informed consent from individuals who donate their biological samples. Donors must fully understand how their samples will be used, stored, and shared in research studies. However, this process can be complicated when genetic data is involved, as many people are not fully aware of the implications of providing such data.

For instance, the HeLa Cell Controversy, the famous HeLa cells, taken from Henrietta Lacks without her knowledge or consent in the 1950s, raised global awareness about the importance of informed consent. This case led to increased scrutiny of the ethics of biobanking, highlighting concerns about individual rights and ownership of genetic materials.

Additionally, according to a study by The Journal of Law, Medicine & Ethics, around 65% of participants in biomedical research are uncertain about what their consent means and how their biological materials will be used in the future. This lack of awareness can lead to reluctance among potential donors, ultimately limiting the availability of samples for research.

Biological samples, particularly genomic data, contain sensitive personal information. Ensuring the privacy and security of this data is a major concern for both individuals and regulatory authorities. The risk of data breaches or unauthorized access to genetic data can deter individuals from donating samples, further limiting the growth of biobanks.

For instance, a Colorado-based pathology laboratory is notifying more than 1.8 million patients that their sensitive information was compromised one of the largest breaches reported by a medical testing lab to US federal regulators, making the healthcare industry especially vulnerable to hackers. In biobanking, the storage of genetic and personal health data raises similar concerns about potential breaches.

Segment Analysis

The North America biobanking market is segmented based on specimen type, product & services, storage type, application, end-user and region.

Application:

The therapeutic research segment is expected to dominate the North America biobanking market share

Therapeutic research relies heavily on the use of biological samples to identify drug targets and biomarkers and understand the molecular mechanisms of diseases. As the biotechnology and pharmaceutical industries in North America continue to expand, the demand for biobank resources for drug discovery and preclinical research has increased significantly. Biobanks provide access to vast repositories of samples, enabling researchers to develop and test new therapies.

For instance, biobanks like the Gulf Coast Consortium in the U.S. provide critical biological samples to pharmaceutical companies, facilitating the development of drugs for various diseases, including cancer, neurodegenerative diseases and infectious diseases. Biobanks are integral to the growth, offering critical support in drug discovery through the availability of high-quality human samples.

Biobanks play a crucial role in clinical trials, where they provide reference samples to assess the safety and efficacy of experimental drugs or therapies. The availability of biomarker-specific samples allows researchers to identify patient subgroups most likely to respond to treatments, which is a key element of personalized medicine. For instance, according to the National Library of Medicine (NLM), as of January 2024, there are 20,465 clinical trials recruiting patients in the U.S.

Biomarker discovery is another area where biobanks play a central role in therapeutic research. Biomarkers are biological indicators used to diagnose diseases, predict disease progression, and assess therapeutic responses. Biobanks provide critical resources to identify novel biomarkers, which can be used in drug development and to guide therapeutic decisions.

For instance, the Cancer Genome Atlas (TCGA), a biobank project led by the National Cancer Institute (NCI), has collected data and tissue samples from thousands of cancer patients to identify genetic biomarkers related to various cancer types. This data is essential for the development of targeted therapies.

Competitive Landscape

The major North America players in the biobanking market include Thermo Fisher Scientific Inc., QIAGEN N.V., PHC Corporation, Merck KGaA, Avantor, Inc., Cryoport Systems, LLC., Tecan Group Ltd., Azenta US Inc., Greiner Bio-One North America Inc., Hamilton Company and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The North America biobanking market report delivers a detailed analysis with 45 key tables, more than 42 visually impactful figures, and 149 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.